Advanced search
Publication Cover
Molecular and Cellular Biology Volume 25, 2005 - Issue 21
Submit an article Journal homepage
855
Views
1,324
CrossRef citations to date
0
Altmetric
Signal Transduction

CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

Richard V. Parry1 Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania19104;2 Department of Pathology and Laboratory Medicine
,
Jens M. Chemnitz1 Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania19104;2 Department of Pathology and Laboratory Medicine
,
Kenneth A. Frauwirth1 Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania19104;3 Department of Cancer Biology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania19104-6160
,
Anthony R. Lanfranco1 Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania19104;2 Department of Pathology and Laboratory Medicine
,
Inbal Braunstein1 Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania19104;2 Department of Pathology and Laboratory Medicine
,
Sumire V. Kobayashi4 Rosetta Inpharmatics, Kirkland, Washington98034
,
Peter S. Linsley4 Rosetta Inpharmatics, Kirkland, Washington98034
,
Craig B. Thompson1 Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania19104;3 Department of Cancer Biology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania19104-6160
&
James L. Riley1 Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania19104;2 Department of Pathology and Laboratory MedicineCorrespondence[email protected]
 show all
Pages 9543-9553 | Received 14 Mar 2005, Accepted 18 Aug 2005, Published online: 27 Mar 2023

Citations (1324)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (64)

Steffen Nielsen, Mateusz K. Sitarz, Priyanshu M. Sinha, Charlemagne A. Folefac, Morten Høyer, Brita S. Sørensen & Michael R. Horsman. (2023) Using immunotherapy to enhance the response of a C3H mammary carcinoma to proton radiation. Acta Oncologica 62:11, pages 1581-1586.
Read now
Viola Trevisani, Lorenzo Iughetti, Laura Lucaccioni & Barbara Predieri. (2023) Endocrine immune-related adverse effects of immune-checkpoint inhibitors. Expert Review of Endocrinology & Metabolism 0:0, pages 1-11.
Read now
Vincenzo Fiorentino, Pietro Tralongo, Luigi Maria Larocca, Cristina Pizzimenti, Maurizio Martini & Francesco Pierconti. (2023) First-line ICIs in renal cell carcinoma. Human Vaccines & Immunotherapeutics 19:2.
Read now
Yaruq Jabeen, Numan Yousaf, Mohd Sani Sarjadi, Jualang Azlan Gansau & Lucky Poh Wah Goh. (2023) Bioactive compounds derived from marine source: a potential immunotherapy treatment. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-12.
Read now
Wu Yi, Tianxin Yang, Sisi Lin, Rui Hao, Jin Yu, Ying Wang & Xiangming Tong. (2022) New Approaches for Treatment of Advanced Extranodal NK/T-Cell Lymphoma. Cancer Management and Research 14, pages 401-407.
Read now
Joachim Stoltenborg Granhøj, Agnete Witness Præst Jensen, Mario Presti, Özcan Met, Inge Marie Svane & Marco Donia. (2022) Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions. Expert Opinion on Biological Therapy 22:5, pages 627-641.
Read now
Meng-ke Fan, Li-li Qi, Qi Zhang & Ling Wang. (2021) The Updated Status and Future Direction of Immunotherapy Targeting B7-H1/PD-1 in Osteosarcoma. Cancer Management and Research 13, pages 757-764.
Read now
Maya Glover, Stephanie Avraamides & John Maher. (2021) How Can We Engineer CAR T Cells to Overcome Resistance?. Biologics: Targets and Therapy 15, pages 175-198.
Read now
Daner A. Silveira, Fernanda M. Ribeiro, Éder M. Simão, Viviane L. D. Mattos & Evamberto G. Góes. (2021) Expression of genes and pathways associated with the B7-CD28 superfamily in response to irradiation of blood cells using 137Cs. International Journal of Radiation Biology 97:2, pages 149-155.
Read now
Leilei Ai, Jian Chen, Hao Yan, Qiaojun He, Peihua Luo, Zhifei Xu & Xiaochun Yang. (2020) Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy. Drug Design, Development and Therapy 14, pages 3625-3649.
Read now
Patrick C. Gedeon, Cosette D. Champion, Kristen E. Rhodin, Karolina Woroniecka, Hanna R. Kemeny, Alexa N. Bramall, Joshua D. Bernstock, Bryan D. Choi & John H. Sampson. (2020) Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. Expert Review of Clinical Pharmacology 13:10, pages 1147-1158.
Read now
Ahmed Sayed, Malak Munir, Noor Eweis, Doaa Wael, Omar Shazly, Ahmed K. Awad, Marihan A. Elbadawy & Sanaa Eissa. (2020) An overview on precision therapy in bladder cancer. Expert Review of Precision Medicine and Drug Development 5:5, pages 347-361.
Read now
Sumin Son, Jinho Park, Hyodeok Seo, Hyun Tae Lee, Yong-Seok Heo & Hak-Sung Kim. (2020) A small-sized protein binder specific for human PD-1 effectively suppresses the tumour growth in tumour mouse model. Journal of Drug Targeting 28:4, pages 419-427.
Read now
Karolina I. Smolag, Christine M. Mueni, Karin Leandersson, Karin Jirström, Catharina Hagerling, Matthias Mörgelin, Paul N. Barlow, Myriam Martin & Anna M. Blom. (2020) Complement inhibitor factor H expressed by breast cancer cells differentiates CD14+ human monocytes into immunosuppressive macrophages. OncoImmunology 9:1.
Read now
Yi Jiang, Ning Zhang, Hailin Pang, Xiaobo Gao & Helong Zhang. (2019) Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis. Therapeutics and Clinical Risk Management 15, pages 293-302.
Read now
Wenli Zuo & Lingdi Zhao. (2019) Recent advances and application of PD-1 blockade in sarcoma. OncoTargets and Therapy 12, pages 6887-6896.
Read now
Ruidi Jiao, Hui Luo, Wenbo Xu & Hong Ge. (2019) Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities. OncoTargets and Therapy 12, pages 6023-6032.
Read now
Lingli Yan & Bainan Liu. (2019) Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors. OncoTargets and Therapy 12, pages 193-204.
Read now
Grégoire Marret, Edith Borcoman & Christophe Le Tourneau. (2019) Pembrolizumab for the treatment of cervical cancer. Expert Opinion on Biological Therapy 19:9, pages 871-877.
Read now
Nazanin Majd & John de Groot. (2019) Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma. Expert Opinion on Pharmacotherapy 20:13, pages 1609-1624.
Read now
Caroline M Hull & John Maher. (2019) Novel approaches to promote CAR T-cell function in solid tumors. Expert Opinion on Biological Therapy 19:8, pages 789-799.
Read now
Krishna Sury & Mark A. Perazella. (2019) The nephrotoxicity of new immunotherapies. Expert Review of Clinical Pharmacology 12:6, pages 513-521.
Read now
Larissa A. Habib, Natalie Wolkow, Suzanne K. Freitag & Michael K. Yoon. (2019) Advances in Immunotherapy and Periocular Malignancy. Seminars in Ophthalmology 34:4, pages 327-333.
Read now
Davide Busato, Monica Mossenta, Lorena Baboci, Federica Di Cintio, Giuseppe Toffoli & Michele Dal Bo. (2019) Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Review of Clinical Pharmacology 12:5, pages 453-470.
Read now
Francesca R. Mariotti, Stefania Petrini, Tiziano Ingegnere, Nicola Tumino, Francesca Besi, Francesca Scordamaglia, Enrico Munari, Silvia Pesce, Emanuela Marcenaro, Alessandro Moretta, Paola Vacca & Lorenzo Moretta. (2019) PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression. OncoImmunology 8:3.
Read now
Niklas Bruse, Guus P. Leijte, Peter Pickkers & Matthijs Kox. (2019) New frontiers in precision medicine for sepsis-induced immunoparalysis. Expert Review of Clinical Immunology 15:3, pages 251-263.
Read now
Zhi-liang Wang, Guan-zhang Li, Qiang-wei Wang, Zhao-shi Bao, Zheng Wang, Chuan-bao Zhang & Tao Jiang. (2019) PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. OncoImmunology 8:2.
Read now
Peng Yue, Taylor Harper, Silvia M. Bacot, Monica Chowdhury, Shiowjen Lee, Adovi Akue, Mark A. Kukuruga, Tao Wang & Gerald M. Feldman. (2019) BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways. OncoImmunology 8:1.
Read now
Lidia Rita Corsini, Daniele Fanale, Francesco Passiglia, Lorena Incorvaia, Vincenzo Gennusa, Viviana Bazan & Antonio Russo. (2018) Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. Expert Opinion on Drug Safety 17:12, pages 1197-1209.
Read now
Adam M. Swartz, Steven H. Shen, Miguel A. Salgado, Kendra L. Congdon & Luis Sanchez-Perez. (2018) Promising vaccines for treating glioblastoma. Expert Opinion on Biological Therapy 18:11, pages 1159-1170.
Read now
Kiichiro Ninomiya & Katsuyuki Hotta. (2018) Pembrolizumab for the first-line treatment of non-small cell lung cancer. Expert Opinion on Biological Therapy 18:10, pages 1015-1021.
Read now
Ziwen Zhu & Weiguo Dong. (2018) Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma. OncoTargets and Therapy 11, pages 1563-1570.
Read now
Kevin Zarrabi & Shenhong Wu. (2018) An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma. Expert Opinion on Biological Therapy 18:6, pages 695-705.
Read now
Erika J. Crosby, Junping Wei, Xiao Yi Yang, Gangjun Lei, Tao Wang, Cong-Xiao Liu, Pankaj Agarwal, Alan J. Korman, Michael A. Morse, Kenneth Gouin, Simon R. V. Knott, H. Kim Lyerly & Zachary C. Hartman. (2018) Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. OncoImmunology 7:5.
Read now
Andres Chang, Danielle Schlafer, Christopher R. Flowers & Pamela B. Allen. (2018) Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. Expert Opinion on Investigational Drugs 27:1, pages 55-70.
Read now
Elisabeth Specht Stovgaard, Dorte Nielsen, Estrid Hogdall & Eva Balslev. (2018) Triple negative breast cancer – prognostic role of immune-related factors: a systematic review. Acta Oncologica 57:1, pages 74-82.
Read now
Marianela Robainas, Rafael Otano, Stephen Bueno & Sihem Ait-Oudhia. (2017) Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy. OncoTargets and Therapy 10, pages 1803-1807.
Read now
Niranjan J Sathianathen, Suprita Krishna, J Kyle Anderson, Christopher J Weight, Shilpa Gupta, Badrinath R Konety & Thomas S Griffith. (2017) The current status of immunobased therapies for metastatic renal-cell carcinoma. ImmunoTargets and Therapy 6, pages 83-93.
Read now
Courtney P. Rudick, David L. Cornell & Devendra K. Agrawal. (2017) Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis. Expert Review of Clinical Immunology 13:9, pages 907-919.
Read now
Egle Ramelyte, Sabrina A. Schindler & Reinhard Dummer. (2017) The safety of anti PD-1 therapeutics for the treatment of melanoma. Expert Opinion on Drug Safety 16:1, pages 41-53.
Read now
T. Jelinek & R. Hajek. (2016) PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future. OncoImmunology 5:12.
Read now
G. Santabarbara, P. Maione, A. Rossi, G. Palazzolo & C. Gridelli. (2016) Novel immunotherapy in the treatment of advanced non-small cell lung cancer. Expert Review of Clinical Pharmacology 9:12, pages 1571-1581.
Read now
Ornella Franzese, Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, Virginia Ferraresi, Helena Stabile, Angela Gismondi, Angela Santoni & Paola Nisticò. (2016) Polyfunctional Melan-A-specific tumor-reactive CD8+ T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. OncoImmunology 5:5.
Read now
Abdallah Abou Zahr, Carolina Bernabe Ramirez, Jocelyn Wozney, Thomas Prebet & Amer M. Zeidan. (2016) New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities. Expert Review of Hematology 9:4, pages 377-388.
Read now
Tong Seng Lim, Valerie Chew, Je Lin Sieow, Siting Goh, Joe Poh-Sheng Yeong, Ai Ling Soon & Paola Ricciardi-Castagnoli. (2016) PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity. OncoImmunology 5:3.
Read now
Giuseppina Improta, Isabella Leone, Marco Donia, Stefania Gieri, Giuseppe Pelosi & Filippo Fraggetta. (2015) New developments in the management of advanced melanoma – role of pembrolizumab. OncoTargets and Therapy 8, pages 2535-2543.
Read now
Tara C Gangadhar & April KS Salama. (2015) Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. OncoTargets and Therapy 8, pages 929-937.
Read now
Nicolas Guibert & Julien Mazières. (2015) Nivolumab for treating non-small cell lung cancer. Expert Opinion on Biological Therapy 15:12, pages 1789-1797.
Read now
Alison Sehgal, Theresa L Whiteside & Michael Boyiadzis. (2015) Programmed death-1 checkpoint blockade in acute myeloid leukemia. Expert Opinion on Biological Therapy 15:8, pages 1191-1203.
Read now
Rosa M Michel Ortega & Harry A Drabkin. (2015) Nivolumab in renal cell carcinoma. Expert Opinion on Biological Therapy 15:7, pages 1049-1060.
Read now
Parisa Momtaz & Michael A Postow. (2014) Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmacogenomics and Personalized Medicine 7, pages 357-365.
Read now
Brian S Henick, Roy S Herbst & Sarah B Goldberg. (2014) The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opinion on Therapeutic Targets 18:12, pages 1407-1420.
Read now
Tetsuya Tabeya, Motohisa Yamamoto, Yasuyoshi Naishiro, Keisuke Ishigami, Yui Shimizu, Hidetaka Yajima, Chisako Suzuki, Nobuhiko Seki, Kenichi Takano, Tetsuo Himi, Kohzoh Imai, Hiroki Takahashi & Yasuhisa Shinomura. (2014) The role of cytotoxic T cells in IgG4-related dacryoadenitis and sialadenitis, the so-called Mikulicz's disease. Modern Rheumatology 24:6, pages 953-960.
Read now
Belal Chaudhary, May Abd Al Samid, Basel K al-Ramadi & Eyad Elkord. (2014) Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Expert Opinion on Biological Therapy 14:7, pages 931-945.
Read now
Jens Vent-Schmidt, Jonathan M. Han, Katherine G. MacDonald & Megan K. Levings. (2014) The Role of FOXP3 in Regulating Immune Responses. International Reviews of Immunology 33:2, pages 110-128.
Read now
Nikolaos Patsoukis, Lequn Li, Duygu Sari, Victoria Petkova & Vassiliki A. Boussiotis. (2013) PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2. Molecular and Cellular Biology 33:16, pages 3091-3098.
Read now
Omid Hamid & Richard D Carvajal. (2013) Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opinion on Biological Therapy 13:6, pages 847-861.
Read now
Michelle T. Shepard & Elizabeth A. Bonney. (2013) PD-1 Regulates T Cell Proliferation in a Tissue and Subset-Specific Manner During Normal Mouse Pregnancy. Immunological Investigations 42:5, pages 385-408.
Read now
Laurence Zitvogel & Guido Kroemer. (2012) Targeting PD-1/PD-L1 interactions for cancer immunotherapy. OncoImmunology 1:8, pages 1223-1225.
Read now
Xiang-Yang Wang, Daming Zuo, Devanand Sarkar & Paul B Fisher. (2011) Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opinion on Pharmacotherapy 12:17, pages 2695-2706.
Read now
Stephen J. Demarest, Kandasamy Hariharan & Jianying Dong. (2011) Emerging antibody combinations in oncology. mAbs 3:4, pages 338-351.
Read now
Lindy G Durrant, Victoria A Pudney & Ian Spendlove. (2011) Using monoclonal antibodies to stimulate antitumor cellular immunity. Expert Review of Vaccines 10:7, pages 1093-1106.
Read now
Elizabeth A Mittendorf & Padmanee Sharma. (2010) Mechanisms of T-cell inhibition: implications for cancer immunotherapy. Expert Review of Vaccines 9:1, pages 89-105.
Read now
Claire Gorman, Timothy Vyse & Andrew Cope. (2006) What does the immunogenetic basis of rheumatoid arthritis teach us about the immunobiology of the disease?. Expert Review of Clinical Immunology 2:5, pages 717-725.
Read now

Articles from other publishers (1260)

Anoop Kallingal, Mateusz Olszewski, Natalia Maciejewska, Wioletta Brankiewicz & Maciej Baginski. (2023) Cancer immune escape: the role of antigen presentation machinery. Journal of Cancer Research and Clinical Oncology 149:10, pages 8131-8141.
Crossref
Yuxi Gao, Jiayu Zhao, Zichao Huang, Hanqin Zhao, Zhaopei Guo, Sheng Ma, Xing Tang, Wantong Song & Xuesi Chen. (2022) In Situ Reprogramming of Tumors for Activating the OX40/OX40 Ligand Checkpoint Pathway and Boosting Antitumor Immunity. ACS Biomaterials Science & Engineering 9:7, pages 4108-4116.
Crossref
Mohamed J. Saadh, Khadijehsadat Kazemi, Hossein Khorramdelazad, Mohammad Javad Mousavi, Negar Noroozi, Maryam Masoumi & Jafar Karami. (2023) Role of T cells in the pathogenesis of systemic lupus erythematous: Focus on immunometabolism dysfunctions. International Immunopharmacology 119, pages 110246.
Crossref
Li Yin, Gui-lai Chen, Zhuo Xiang, Yu-lin Liu, Xing-yu Li, Jing-wang Bi & Qiang Wang. (2023) Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer. Biomedicine & Pharmacotherapy 162, pages 114648.
Crossref
Se‐Hoon Lee, Yeongmin Kim, Bu‐Nam Jeon, Gihyeon Kim, Jinyoung Sohn, Youngmin Yoon, Sujeong Kim, Yunjae Kim, Hyemin Kim, Hongui Cha, Na‐Eun Lee, Hyunsuk Yang, Joo‐Yeon Chung, A‐Reum Jeong, Yun Yeon Kim, Sang Gyun Kim, Yeonhee Seo, Sehhoon Park, Hyun Ae Jung, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Hansoo Park & Kyoung Wan Yoon. (2023) Intracellular Adhesion Molecule‐1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8 + T Cells . Advanced Science 10:17.
Crossref
Yaling Pu, Danyang Cai, Lingling Jin, Fenfen Xu, Enru Ye, Lina Wu, Licai Mo, Suzhi Liu, Qunyi Guo & Gang Wu. (2023) TREM-1 as a potential prognostic biomarker associated with immune infiltration in clear cell renal cell carcinoma. World Journal of Surgical Oncology 21:1.
Crossref
Enrique Montero & Jeffrey S. Isenberg. (2023) The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era. Cancer Immunology, Immunotherapy.
Crossref
Nengqi Lin, Wei Yin, Heather Miller, Maria G. Byazrova, Andrés A. Herrada, Kamel Benlagha, Pamela Lee, Fei Guan, Jiahui Lei, Quan Gong, Youqing Yan, Alexander Filatov & Chaohong Liu. (2023) The role of regulatory T cells and follicular T helper cells in HBV infection. Frontiers in Immunology 14.
Crossref
Youliang Zhao, Yaqian Qu, Changfu Hao & Wu Yao. (2023) PD-1/PD-L1 axis in organ fibrosis. Frontiers in Immunology 14.
Crossref
Junfeng Zhang, Feifei Lei & Huabing Tan. (2023) The development of CD8 T-cell exhaustion heterogeneity and the therapeutic potentials in cancer. Frontiers in Immunology 14.
Crossref
Nikita Mani, Dathan Andrews & Rebecca C. Obeng. (2023) Modulation of T cell function and survival by the tumor microenvironment. Frontiers in Cell and Developmental Biology 11.
Crossref
Suyasha Roy & Lalit Batra. (2023) Protein Phosphatase 2A: Role in T Cells and Diseases. Journal of Immunology Research 2023, pages 1-11.
Crossref
Sebastian Klein, Jasmin Mischke, Finn Beruldsen, Immo Prinz, Dinler A. Antunes, Markus Cornberg & Anke R. M. Kraft. (2023) Individual Epitope-Specific CD8+ T Cell Immune Responses Are Shaped Differently during Chronic Viral Infection. Pathogens 12:5, pages 716.
Crossref
Hongya Ning, Shih-Hsin Chiu, Xiaodong Xu, Yanmei Ma, Ji-Long Chen & Guihong Yang. (2023) The Immunosuppressive Roles of PD-L1 during Influenza A Virus Infection. International Journal of Molecular Sciences 24:10, pages 8586.
Crossref
Kaveh Hadiloo, Safa Tahmasebi & Abdolreza Esmaeilzadeh. (2023) CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy. Cancer Cell International 23:1.
Crossref
Camil Ciprian Mireștean, Roxana Irina Iancu & Dragoș Teodor Iancu. (2023) Radiotherapy and Immunotherapy—A Future Partnership towards a New Standard. Applied Sciences 13:9, pages 5643.
Crossref
Soki Kashima & David A. Braun. (2023) The Changing Landscape of Immunotherapy for Advanced Renal Cancer. Urologic Clinics of North America 50:2, pages 335-349.
Crossref
Breanna Caruso & Amy E. Moran. (2023) Thymic expression of immune checkpoint molecules and their implication for response to immunotherapies. Trends in Cancer.
Crossref
Jovanna A. Tracz, Brianna M. Donnelly, Sam Ngu, Morana Vojnic, A.Gabriella Wernicke & Randy S. D’Amico. (2023) The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma. Journal of Neuro-Oncology 163:1, pages 1-14.
Crossref
Aditya Arra, Holger Lingel, Mandy Pierau & Monika C. Brunner-Weinzierl. (2023) PD-1 limits differentiation and plasticity of Tc17 cells. Frontiers in Immunology 14.
Crossref
Marc C. Pulanco, Anne T. Madsen, Ankit Tanwar, Devin T. Corrigan & Xingxing Zang. (2023) Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies. Cellular & Molecular Immunology 20:7, pages 694-713.
Crossref
Chirag H. PatelJonathan D. Powell. (2023) Immune Cell Metabolism and Immuno-Oncology. Annual Review of Cancer Biology 7:1, pages 93-110.
Crossref
Györgyi Műzes & Ferenc Sipos. (2023) Autoimmunity and Carcinogenesis: Their Relationship under the Umbrella of Autophagy. Biomedicines 11:4, pages 1130.
Crossref
Menglu Pan, Huanhuan Zhao, Ruimin Jin, Patrick S. C. Leung & Zongwen Shuai. (2023) Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future. Frontiers in Immunology 14.
Crossref
Mohammad Arif Rahman, Massimiliano Bissa, Isabela Silva de Castro, Sabrina Helmold Hait, James D. Stamos, Farzana Bhuyan, Ruth Hunegnaw, Sarkis Sarkis, Anna Gutowska, Melvin N. Doster, Ramona Moles, Tanya Hoang, Lisa M. Miller Jenkins, Ettore Appella, David J. Venzon, Hyoyoung Choo-Wosoba, Timothy Cardozo, Marc M. Baum, Daniel H. Appella, Marjorie Robert-Guroff & Genoveffa Franchini. (2023) Vaccine plus microbicide effective in preventing vaginal SIV transmission in macaques. Nature Microbiology 8:5, pages 905-918.
Crossref
Satoshi Kawata, Junji Kozawa, Sho Yoneda, Yukari Fujita, Risa Kashiwagi-Takayama, Takekazu Kimura, Yoshiya Hosokawa, Megu Y. Baden, Sae Uno, Rikako Uenaka, Kazuyuki Namai, Yoko Koh, Yoshito Tomimaru, Haruhiko Hirata, Motohide Uemura, Satoshi Nojima, Eiichi Morii, Hidetoshi Eguchi, Akihisa Imagawa & Iichiro Shimomura. (2023) Inflammatory Cell Infiltration Into Islets Without PD-L1 Expression Is Associated With the Development of Immune Checkpoint Inhibitor–Related Type 1 Diabetes in Genetically Susceptible Patients. Diabetes 72:4, pages 511-519.
Crossref
Laura Bergantini, Miriana d'Alessandro, Dalila Cavallaro, Elena Pordon, Lucia Cassai, Sara Gangi, Federica Meloni, Francesca Montagnani, Piero Paladini, Rosa Metella Refini, Luca Luzzi, Antonella Fossi, Elena Bargagli & David Bennett. (2023) Immune checkpoint analysis of T‐cell responses to pp65 and IE‐1 antigens in end‐stage lung diseases. Scandinavian Journal of Immunology 97:4.
Crossref
Della White, Alexandra Cote-Martin, Marina Bleck, Nicole Garaffa, Abdulsalam Shaaban, Helen Wu, Dongmei Liu, David Young, Justin Scheer, Ivo C. Lorenz, Andrew Nixon, Jay S. Fine, Fergus R. Byrne, M.Lamine Mbow & Miguel E. Moreno-Garcia. (2023) Programmed Cell Death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cells. Molecular Immunology 156, pages 31-38.
Crossref
Elaine Lau, George Kwong, Tristan W. Fowler, Bee-Chun Sun, Paul D. Donohoue, Ryan T. Davis, Mara Bryan, Shannon McCawley, Starlynn C. Clarke, Carolyn Williams, Lynda Banh, Matthew Irby, Leslie Edwards, Meghan Storlie, Bryan Kohrs, Graham W.J. Lilley, Stephen C. Smith, Scott Gradia, Chris K. Fuller, Justin Skoble, Elizabeth Garner, Megan van Overbeek & Steven B. Kanner. (2023) Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness. Cytotherapy.
Crossref
Błażej Ochman, Sylwia Mielcarska, Agnieszka Kula, Miriam Dawidowicz, Julia Robotycka, Jerzy Piecuch, Monika Szrot, Sylwia Dzięgielewska-Gęsiak, Małgorzata Muc-Wierzgoń, Dariusz Waniczek & Elżbieta Świętochowska. (2023) Do Elevated YKL-40 Levels Drive the Immunosuppressive Tumor Microenvironment in Colorectal Cancer? Assessment of the Association of the Expression of YKL-40, MMP-8, IL17A, and PD-L1 with Coexisting Type 2 Diabetes, Obesity, and Active Smoking. Current Issues in Molecular Biology 45:4, pages 2781-2797.
Crossref
Jiawen Huang & Juan Huang. 2023. Immune Checkpoint Inhibitors - New Insights and Recent Progress. Immune Checkpoint Inhibitors - New Insights and Recent Progress.
Yibing Wei, Dingka Song, Ran Wang, Tingting Li, Hui Wang & Xiaoguang Li. (2023) Dietary fungi in cancer immunotherapy: From the perspective of gut microbiota. Frontiers in Oncology 13.
Crossref
Xiangxiao Hu, Lina Wang, Bin Shang, Junren Wang, Jian Sun, Bin Liang, Lili Su, Wenjie You & Shujuan Jiang. (2023) Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors. Frontiers in Immunology 14.
Crossref
Xi-Wen Zhang, Yi-Shi Wu, Tian-Min Xu & Man-Hua Cui. (2023) CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy. Biomolecules 13:3, pages 465.
Crossref
Xiaoqing Chen, Xue Liu, Yichao Jiang, Ningshao Xia, Chao Liu & Wenxin Luo. (2023) Abnormally primed CD8 T cells: The Achilles’ heel of CHB. Frontiers in Immunology 14.
Crossref
Joy Edwards-Hicks, Petya Apostolova, Joerg M. Buescher, Hannes Maib, Michal A. Stanczak, Mauro Corrado, Ramon I. Klein Geltink, Maria Elena Maccari, Matteo Villa, Gustavo E. Carrizo, David E. Sanin, Francesc Baixauli, Beth Kelly, Jonathan D. Curtis, Fabian Haessler, Annette Patterson, Cameron S. Field, George Caputa, Ryan L. Kyle, Melanie Soballa, Minsun Cha, Harry Paul, Jacob Martin, Katarzyna M. Grzes, Lea Flachsmann, Michael Mitterer, Liang Zhao, Frances Winkler, David Ali Rafei-Shamsabadi, Frank Meiss, Bertram Bengsch, Robert Zeiser, Daniel J. Puleston, David O’Sullivan, Edward J. Pearce & Erika L. Pearce. (2023) Phosphoinositide acyl chain saturation drives CD8+ effector T cell signaling and function. Nature Immunology 24:3, pages 516-530.
Crossref
Emily N. Arner & Jeffrey C. Rathmell. (2023) Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell 41:3, pages 421-433.
Crossref
Gisha Rose Antony, Ajeesh Babu Littleflower, Sulfath Thottungal Parambil & Lakshmi Subhadradevi. (2023) PD-1/PD-L1 blockade inhibits epithelial-mesenchymal transition and improves chemotherapeutic response in breast cancer. Medical Oncology 40:4.
Crossref
Bo Wu, Xiang Shi, Meixi Jiang & Hongxu Liu. (2023) Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. Molecular Cancer 22:1.
Crossref
Xianyong Zhou, Chen Li, Tong Chen, Wenhao Li, Xiaolong Wang & Qifeng Yang. (2023) Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy. Molecular Cancer 22:1.
Crossref
Xiaoxia Chi, Shahang Luo, Peng Ye, Wei-Lun Hwang, Jong-Ho Cha, Xiuwen Yan & Wen-Hao Yang. (2023) T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications. Frontiers in Immunology 14.
Crossref
Firas Hamdan & Vincenzo Cerullo. (2023) Cancer immunotherapies: A hope for the uncurable?. Frontiers in Molecular Medicine 3.
Crossref
Andrew Knight, Lilit Karapetyan & John M. Kirkwood. (2023) Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers 15:4, pages 1106.
Crossref
Kah Yee Goh, Terence You De Cheng, Su Chin Tham & Darren Wan-Teck Lim. (2023) Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. Biomedicines 11:2, pages 508.
Crossref
Long Chen, Hongwei Liu, Yanwen Li, Xuelei Lin, Shunjin Xia, Siyi Wanggou & Xuejun Li. (2023) Functional characterization of TSPAN7 as a novel indicator for immunotherapy in glioma. Frontiers in Immunology 14.
Crossref
Mateusz Kciuk, Damian Kołat, Żaneta Kałuzińska-Kołat, Mateusz Gawrysiak, Rafał Drozda, Ismail Celik & Renata Kontek. (2023) PD-1/PD-L1 and DNA Damage Response in Cancer. Cells 12:4, pages 530.
Crossref
Mengyun Wu, Xiu Gao, Yuxu Tang, Wenyan Wu, Ji Zhou, Yu Shao, Chuangli Hao, Yi Yang & Jinping Zhang. (2023) Cbl-b inhibited CD4+ T cell activation by regulating the expression of miR-99a/miR-125b. International Immunopharmacology 115, pages 109677.
Crossref
Stefanie Lesch, Alessia Nottebrock, Felicitas Rataj, Constanze Heise, Stefan Endres & Sebastian Kobold. (2022) PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models. Cellular Oncology 46:1, pages 227-235.
Crossref
Rajdeep Chakraborty, Charbel Darido, Fei Liu, Maciej Maselko & Shoba Ranganathan. (2023) Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research. Cancers 15:3, pages 852.
Crossref
Dragan Copic, Martin Direder, Katharina Klas, Daniel Bormann, Maria Laggner, Hendrik Jan Ankersmit & Michael Mildner. (2023) Antithymocyte Globulin Inhibits CD8+ T Cell Effector Functions via the Paracrine Induction of PDL-1 on Monocytes. Cells 12:3, pages 382.
Crossref
Clémentine Halliez, Hazem Ibrahim, Timo Otonkoski & Roberto Mallone. (2023) In vitro beta-cell killing models using immune cells and human pluripotent stem cell-derived islets: Challenges and opportunities. Frontiers in Endocrinology 13.
Crossref
Wenya Wei, Md Mehedi Hassan, Jizhong Wu, Xuefan Mu, Huanhuan Li & Quansheng Chen. (2022) Competitive Ratiometric Aptasensing with Core-Internal Standard-Shell Structure Based on Surface-Enhanced Raman Scattering. Journal of Agricultural and Food Chemistry 71:1, pages 857-866.
Crossref
Andrea M. Amitrano & Minsoo Kim. (2023) Metabolic Challenges in Anticancer CD8 T Cell Functions. Immune Network 23:1.
Crossref
Elham Sajjadi, Chiara Frascarelli, Konstantinos Venetis, Giuseppina Bonizzi, Mariia Ivanova, Gianluca Vago, Elena Guerini-Rocco & Nicola Fusco. (2023) Computational pathology to improve biomarker testing in breast cancer: how close are we?. European Journal of Cancer Prevention Publish Ahead of Print.
Crossref
Mariam Oladejo, Wyatt Paulishak & Laurence Wood. (2023) Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Seminars in Cancer Biology 88, pages 81-95.
Crossref
Barbara Catalfamo & Egesta Lopci. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology 1 40 .
Kazuhide Miyamoto, Hodaka Hayabuchi, Yukiko Tokifuji, Makoto Ando, Nobuyuki Onishi, Tadashi Okamura, Akihiko Yoshimura & Shunsuke Chikuma. (2022) A protein kinase D inhibitor suppresses AKT on T cells and antagonizes cancer immunotherapy by anti-PD-1. International Immunology 34:12, pages 609-619.
Crossref
Jianqing Zheng, Bifen Huang, Lihua Xiao, Min Wu & Jiancheng Li. (2022) Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials. Frontiers in Oncology 12.
Crossref
Haohao Li, Alison Zhao, Menghua Li, Lizhi Shi, Qiuju Han & Zhaohua Hou. (2022) Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy. Frontiers in Immunology 13.
Crossref
I. V. Savchenko, V. V. Breder, I. S. Stilidi, K. K. Laktionov, N. E. Kudashkin, A. V. Egorova & S. V. Chulkova. (2022) Second line drug therapy for biliary cancer. Meditsinskiy sovet = Medical Council:22, pages 136-147.
Crossref
Veronika Voronova, Anastasia Vislobokova, Kerim Mutig, Mikhail Samsonov, Kirill Peskov, Marina Sekacheva, Maria Materenchuk, Natalya Bunyatyan & Svetlana Lebedeva. (2022) Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance. Frontiers in Oncology 12.
Crossref
Aimin Jiang, Na Liu, Jingjing Wang, Xiaoqiang Zheng, Mengdi Ren, Wei Zhang & Yu Yao. (2022) The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?. Frontiers in Immunology 13.
Crossref
Natasha Salame, Jean-Pierre Bikorimana, Nehme El-Hachem, Wael Saad, Mazen Kurdi, Jing Zhao, Nicoletta Eliopoulos, Riam Shammaa & Moutih Rafei. (2022) UM171A-induced ROS promote antigen cross-presentation of immunogenic peptides by bone marrow-derived mesenchymal stromal cells. Stem Cell Research & Therapy 13:1.
Crossref
Lu Zhang, Wen Zhang, Ziye Li, Shumeng Lin, Tiansheng Zheng, Bingjie Hao, Yaqin Hou, Yanfei Zhang, Kai Wang, Chenge Qin, Liduo Yue, Jing Jin, Ming Li & Lihong Fan. (2022) Mitochondria dysfunction in CD8+ T cells as an important contributing factor for cancer development and a potential target for cancer treatment: a review. Journal of Experimental & Clinical Cancer Research 41:1.
Crossref
Yue Huang, Xiaohui Si, Mi Shao, Xinyi Teng, Gang Xiao & He Huang. (2022) Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells. Journal of Hematology & Oncology 15:1.
Crossref
Ying ZhangXiang ZhangMing KuangJun Yu. (2022) Emerging Insights on Immunotherapy in Liver Cancer. Antioxidants & Redox Signaling 37:16-18, pages 1325-1338.
Crossref
Sajad Najafi, Jamal Majidpoor & Keywan Mortezaee. (2022) The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences 310, pages 121138.
Crossref
Eslam E. Abd El-Fattah & Hend Mostafa Selim. (2022) Reprograming immune microenvironment modulates CD47 cancer stem cells in hepatocellular carcinoma. International Immunopharmacology 113, pages 109475.
Crossref
Elnaz Rouzbahani, Jamal Majidpoor, Sajad Najafi & Keywan Mortezaee. (2022) Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Biomedicine & Pharmacotherapy 156, pages 113906.
Crossref
Mónica Cejuela, Andrea Vethencourt & Sonia Pernas. (2022) Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer. Current Oncology Reports 24:12, pages 1801-1819.
Crossref
Han Zheng, Chi Zhang, Qianqian Wang, Shuyan Feng, Yi Fang & Shuo Zhang. (2022) The impact of aging on intestinal mucosal immune function and clinical applications. Frontiers in Immunology 13.
Crossref
Fatemeh Nasiri, Mehrasa Kazemi, Seyed Mohamad Javad Mirarefin, Maral Mahboubi Kancha, Milad Ahmadi Najafabadi, Faeze Salem, Setareh Dashti Shokoohi, Sahar Evazi Bakhshi, Pouya Safarzadeh Kozani & Pooria Safarzadeh Kozani. (2022) CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. Frontiers in Immunology 13.
Crossref
Ornella Franzese & Grazia Graziani. (2022) Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints. Cancers 14:22, pages 5633.
Crossref
Fateme Safaeifard, Bahram Goliaei, Amir R. Aref, Mohammad-Hadi Foroughmand-Araabi, Sama Goliaei, Jochen Lorch, Russell W. Jenkins, David A. Barbie, Seyed Peyman Shariatpanahi & Curzio Rüegg. (2022) Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade. Cells 11:22, pages 3534.
Crossref
Yi Wang, Yuya Wang, Yifei Ren, Qi Zhang, Ping Yi & Chunming Cheng. (2022) Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer. Seminars in Cancer Biology 86, pages 542-565.
Crossref
Francesca Pischiutta, Enrico Caruso, Helena Cavaleiro, Antonio J. Salgado, David J. Loane & Elisa R. Zanier. (2022) Mesenchymal stromal cell secretome for traumatic brain injury: Focus on immunomodulatory action. Experimental Neurology 357, pages 114199.
Crossref
Pujan Sasmal, Sajeev Kumar Babasahib, B.R. Prashantha Kumar & Nulgumnalli Manjunathaiah Raghavendra. (2022) Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction. Bioorganic & Medicinal Chemistry 73, pages 117001.
Crossref
James Miles, Stephen G. Ward & Banafshé Larijani. (2022) The fusion of quantitative molecular proteomics and immune‐oncology : a step towards precision medicine in cancer therapeutics . FEBS Letters 596:21, pages 2721-2735.
Crossref
Xi-Yang Tang, Zhong-Lin Luo, Yan-Lu Xiong, Jie Yang, An-Ping Shi, Kai-Fu Zheng, Yu-Jian Liu, Chen Shu, Nan Ma, Qiang Lu & Jin-Bo Zhao. (2022) The Proliferative Role of Immune Checkpoints in Tumors: Double Regulation. Cancers 14:21, pages 5374.
Crossref
Zeng Zhang, Xin Tan, Zengxin Jiang, Hao Wang & Hengfeng Yuan. (2022) Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future. Frontiers in Pharmacology 13.
Crossref
Konstantinos Tsiakos, Niki Gavrielatou, Ioannis Vathiotis, Loukas Chatzis, Stamatios Chatzis, Garyfallia Poulakou, Elias Kotteas & Nikolaos Syrigos. (2022) Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities. Vaccines 10:10, pages 1673.
Crossref
Zhenyi Niu, Runsen Jin, Yan Zhang & Hecheng Li. (2022) Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. Signal Transduction and Targeted Therapy 7:1.
Crossref
Laura I. Yousif, Anniek A. Tanja, Rudolf A. de Boer, Arco J. Teske & Wouter C. Meijers. (2022) The role of immune checkpoints in cardiovascular disease. Frontiers in Pharmacology 13.
Crossref
Beth Ann Jirón Tamburini. (2021) Contributions of PD‐L1 reverse signaling to dendritic cell trafficking. The FEBS Journal 289:20, pages 6256-6266.
Crossref
Wei Li, Fenglei Wu, Shaolin Zhao, Peiqin Shi, Shengjun Wang & Dawei Cui. (2022) Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy. Cytokine & Growth Factor Reviews 67, pages 49-57.
Crossref
Ching-Tse Wu, Cheng-I Chu, Feng-Yu Wang, Hui-Yu Yang, Wei-Sung Tseng, Chuang-Rung Chang & Chien-Chung Chang. (2022) A change of PD-1/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer's Disease. Cell & Bioscience 12:1.
Crossref
Reem Altaf, Sarmad Sheraz Jadoon, Syed Aun Muhammad, Umair Ilyas & Yongtao Duan. (2022) Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment. Frontiers in Oncology 12.
Crossref
Jiqi Shan, Dong Han, Chunyi Shen, Qingyang Lei & Yi Zhang. (2022) Mechanism and strategies of immunotherapy resistance in colorectal cancer. Frontiers in Immunology 13.
Crossref
Chu Xiao, He Tian, Yujia Zheng, Zhenlin Yang, Shuofeng Li, Tao Fan, Jiachen Xu, Guangyu Bai, Jingjing Liu, Ziqin Deng, Chunxiang Li & Jie He. (2022) Glycolysis in tumor microenvironment as a target to improve cancer immunotherapy. Frontiers in Cell and Developmental Biology 10.
Crossref
Ajmeri Sultana Shimu, Hua-xing Wei, Qiangsheng Li, Xucai Zheng & Bofeng Li. (2022) The new progress in cancer immunotherapy. Clinical and Experimental Medicine.
Crossref
Keyu Yuan, Jiangping Wu, Yanjie Zhao, Shuzhen Lyu, Quan Zhou, Feng Shi, Yanping Li & Qingkun Song. (2022) Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test. Diagnostic Pathology 17:1.
Crossref
Michael C. McGee, Tianyi Zhang, Nicholas Magazine, Rezwanul Islam, Mariano Carossino & Weishan Huang. (2022) PD-1 and ICOS counter-regulate tissue resident regulatory T cell development and IL-10 production during flu. Frontiers in Immunology 13.
Crossref
Junjie Liu, Haisu Tao, Tong Yuan, Jiang Li, Jian Li, Huifang Liang, Zhiyong Huang & Erlei Zhang. (2022) Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. Frontiers in Immunology 13.
Crossref
Yanmeizhi Wu, Shan Yu & Hong Qiao. (2022) Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer. Frontiers in Pharmacology 13.
Crossref
Qingxiang Liu, Ming Xue, Qianwen Song, Jianfeng Xie, Yi Yang & Songqiao Liu. (2022) Expression of PD-1 on Memory T Lymphocytes Predicts 28-Day Mortality of Patients with Sepsis: A Prospective Observational Study. Journal of Inflammation Research Volume 15, pages 5043-5052.
Crossref
D.T. Goodman. (2022) Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside. JPRAS Open 33, pages 155-160.
Crossref
Dongfu Jin, Yaxin Jiang, Lu Chang, Jing Wei & Jian Sun. (2022) New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseases. International Immunopharmacology 110, pages 108935.
Crossref
Yuying Gao, Binbin Song, Shigeki Aoki & Kousei Ito. (2022) Conjugation of human serum albumin and flucloxacillin provokes specific immune response in HLA-B*57:01 transgenic mice. Immunology Letters 249, pages 5-11.
Crossref
Aisha Shaikh. (2022) Immunotherapies and renal injury. Current Opinion in Toxicology 31, pages 100362.
Crossref
Franziska Füchsl & Angela M. Krackhardt. (2022) Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. Cancers 14:17, pages 4192.
Crossref
Zheng Sun, Yidi Li, Zining Zhang, Yajing Fu, Xiaoxu Han, Qinghai Hu, Haibo Ding, Hong Shang & Yongjun Jiang. (2022) CD160 Promotes NK Cell Functions by Upregulating Glucose Metabolism and Negatively Correlates With HIV Disease Progression. Frontiers in Immunology 13.
Crossref
Lucas Leite Cunha, Victor Alexandre dos Santos Valsecchi & Laura Sterian Ward. (2022) Investigating population-level immunosenescence: From bench to bedside. Frontiers in Immunology 13.
Crossref
Peter H. Wang, Robert Washburn, Rohan Maniar, Michael Mu, Olivia Ringham, Radomir Kratchmarov, Brian S. Henick & Steven L. Reiner. (2022) Cutting Edge: Promoting T Cell Factor 1+ T Cell Self-Renewal to Improve Programmed Cell Death Protein 1 Blockade. The Journal of Immunology 209:4, pages 660-664.
Crossref
Danielle Rosa Beserra, Ricardo Wesley Alberca, Anna Claudia Calvielli Castelo Branco, Luana de Mendonça Oliveira, Milena Mary de Souza Andrade, Sarah Cristina Gozzi-Silva, Franciane Mouradian Emidio Teixeira, Tatiana Mina Yendo, Alberto José da Silva Duarte & Maria Notomi Sato. (2022) Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity. Journal of Immunology Research 2022, pages 1-9.
Crossref
Lei Wang, Wenjie Sun, Guoan Zhang, Jingrui Huo, Yi Tian, Yan Zhang, Xiaohui Yang & Yingfu Liu. (2022) T‐cell activation is associated with high‐grade serous ovarian cancer survival. Journal of Obstetrics and Gynaecology Research 48:8, pages 2189-2197.
Crossref
Maria Sofia Basile, Placido Bramanti & Emanuela Mazzon. (2022) The Role of Cytotoxic T-Lymphocyte Antigen 4 in the Pathogenesis of Multiple Sclerosis. Genes 13:8, pages 1319.
Crossref
Valentina Vultaggio-Poma & Francesco Di Virgilio. (2022) P2 Receptors: Novel Disease Markers and Metabolic Checkpoints in Immune Cells. Biomolecules 12:7, pages 983.
Crossref
Alkhansa S. Mahmoud, Zuki AB. Zakaria, Hazilawati HJ. Hamzah & Tengku Ahbrizal F.T.A.. 2022. Breast Cancer: Current Trends in Molecular Research. Breast Cancer: Current Trends in Molecular Research 242 258 .
Shuai Shi, Hong-Yan Ma, Yin-zhou Sang, Ying-Bo Ju, Xiao-Yun Liu & Zhi-Gang Zhang. (2022) Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer. BioMed Research International 2022, pages 1-10.
Crossref
Emily Hensler, Habesha Petros, Chyna C. Gray, Chun-Shiang Chung, Alfred Ayala & Eleanor A. Fallon. (2022) The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers. Frontiers in Immunology 13.
Crossref
Enitome E. Bafor, Julio C. Valencia & Howard A. Young. (2022) Double Negative T Regulatory Cells: An Emerging Paradigm Shift in Reproductive Immune Tolerance?. Frontiers in Immunology 13.
Crossref
John S Davies, Farrah Karimipour, Ling Zhang, Nisha Nagarsheth, Scott Norberg, Carylinda Serna, Julius Strauss, Shinheng Chiou, James L Gulley & Christian S Hinrichs. (2022) Non-synergy of PD-1 blockade with T-cell therapy in solid tumors. Journal for ImmunoTherapy of Cancer 10:7, pages e004906.
Crossref
Peter E. Hutchinson & James H. Pringle. (2022) Consideration of possible effects of vitamin D on established cancer, with reference to malignant melanoma. Pigment Cell & Melanoma Research 35:4, pages 408-424.
Crossref
Lingnan Zheng, Xi Yang, Yuanfeng Wei, Jia You, Huawei Li, Jinfeng Liao & Cheng Yi. (2022) Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors. Materials & Design 219, pages 110738.
Crossref
Rashi Yadav & William L. Redmond. (2022) Current Clinical Trial Landscape of OX40 Agonists. Current Oncology Reports 24:7, pages 951-960.
Crossref
Siyuan Weng, Zaoqu Liu, Hui Xu, Xiaoyong Ge, Yuqing Ren, Qin Dang, Long Liu, Jian Zhang, Peng Luo, Jianzhuang Ren & Xinwei Han. (2022) ALOX12: A Novel Insight in Bevacizumab Response, Immunotherapy Effect, and Prognosis of Colorectal Cancer. Frontiers in Immunology 13.
Crossref
Berkay Yahsi & Gurcan Gunaydin. (2022) Immunometabolism – The Role of Branched-Chain Amino Acids. Frontiers in Immunology 13.
Crossref
Min Yuan, Yu Zhao, Hendrik-Tobias Arkenau, Tongnei Lao, Li Chu & Qing Xu. (2022) Signal pathways and precision therapy of small-cell lung cancer. Signal Transduction and Targeted Therapy 7:1.
Crossref
Audrey Melin, Émilie Routier, Séverine Roy, Pauline Pradere, Jerome Le Pavec, Thibaut Pierre, Noémie Chanson, Jean-Yves Scoazec, Olivier Lambotte & Caroline Robert. (2022) Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma. Cancers 14:12, pages 2937.
Crossref
Luca Simula, Emma Ollivier, Philippe Icard & Emmanuel Donnadieu. (2022) Immune Checkpoint Proteins, Metabolism and Adhesion Molecules: Overlooked Determinants of CAR T-Cell Migration?. Cells 11:11, pages 1854.
Crossref
Bairu Shen, Zi Guo, Peng Huang, Minghua Tan, Xiaoshen Zhang, Siyao Lin, Changshan Song, Jiaqing Wang & Minqian Huang. (2022) Immunotherapy and Antivascular Targeted Therapy in Patients’ Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge. Journal of Immunology Research 2022, pages 1-13.
Crossref
Abdullahi Alausa, Ugwu Chukwuebuka Victor, Olumide Samuel Fadahunsi, Nurudeen Owolabi, Adeolu Adeniji, Mercy Olatinwo, Abdeen Tunde Ogunlana, Barakat Olaleke, Toheeb Adewale Balogun, Sunday Ogundepo & Peter Ifeoluwa Adegbola. (2022) Checkpoints and immunity in cancers: Role of GNG12. Pharmacological Research 180, pages 106242.
Crossref
Li-ping Zhao, Jun-hu Hu, Die Hu, Hao-jie Wang, Chang-gang Huang, Ru-hua Luo, Zhao-huang Zhou, Xin-yun Huang, Tian Xie & Jian-shu Lou. (2022) Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies. Biomedicine & Pharmacotherapy 150, pages 112949.
Crossref
Juyoung Hwang, Eun-Koung An, Wei Zhang, Hae-Bin Park, So-Jung Kim, Dhananjay Yadav, Jihoe Kim, Inho Choi, Minseok Kwak, Peter CW. Lee, Xiaoyan Zhang, Jianqing Xu & Jun-O Jin. (2022) Recombinant programmed cell death protein 1 functions as an immune check point blockade and enhances anti-cancer immunity. Biomaterials 285, pages 121550.
Crossref
Junjie Teng, Kai Zhou, Dongxiao Lv, Changshun Wu & Hong Feng. (2022) Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma. Frontiers in Pharmacology 13.
Crossref
Anirban Banerjee, Dongge Li, Yizhan Guo, Zhongcheng Mei, Christine Lau, Kelly Chen, John Westwick, Jeffery B. Klauda, Adam Schrum, Eric R. Lazear & Alexander S. Krupnick. (2022) A reengineered common chain cytokine augments CD8+ T cell–dependent immunotherapy. JCI Insight 7:10.
Crossref
Zarwa Yaseen, Tuba N. Gide, Jordan W. Conway, Alison J. Potter, Camelia Quek, Angela M. Hong, Georgina V. Long, Richard A. Scolyer & James S. Wilmott. (2022) Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma. Frontiers in Molecular Biosciences 9.
Crossref
Yongpan An, Jie Zhu, Xin Wang, Xinpei Sun, Chunxiong Luo, Yukun Zhang, Yuwei Ye, Xiaowei Li, Abudumijiti Abulizi, Zhizhen Huang, Hang Zhang, Baoxue Yang & Zhengwei Xie. (2022) Oridonin Delays Aging Through the AKT Signaling Pathway. Frontiers in Pharmacology 13.
Crossref
Adrien Krug, Gamze Tari, Aymen Saidane, Philippe Gaulard, Jean-Ehrland Ricci, François Lemonnier & Els Verhoeyen. (2022) Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality. Cancers 14:10, pages 2392.
Crossref
Pouya Safarzadeh Kozani, Pooria Safarzadeh Kozani, Milad Ahmadi Najafabadi, Fatemeh Yousefi, Seyed Mohamad Javad Mirarefin & Fatemeh Rahbarizadeh. (2022) Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?. Frontiers in Immunology 13.
Crossref
Tara M Davidson, Nathan Foster, Fabrice Lucien, Svetomir Markovic, Haidong Dong, Jeffrey L Winters, Sean S Park & Jacob J Orme. (2022) Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy. BMJ Open 12:5, pages e050112.
Crossref
Joseph A. Perry, Lindsey Shallberg, Joseph T. Clark, Jodi A. Gullicksrud, Jonathan H. DeLong, Bonnie B. Douglas, Andrew P. Hart, Zachary Lanzar, Keenan O’Dea, Christoph Konradt, Jeongho Park, Juhi R. Kuchroo, Daniel Grubaugh, Arielle Glatman Zaretsky, Igor E. Brodsky, Rene de Waal Malefyt, David A. Christian, Arlene H. Sharpe & Christopher A. Hunter. (2022) PD-L1–PD-1 interactions limit effector regulatory T cell populations at homeostasis and during infection. Nature Immunology 23:5, pages 743-756.
Crossref
Aristeidis E. Boukouris, Maria Theochari, Dimitra Stefanou, Alexandros Papalambros, Evangelos Felekouras, Helen Gogas & Dimitrios C. Ziogas. (2022) Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. Critical Reviews in Oncology/Hematology 173, pages 103663.
Crossref
Kevin S. Bittman. (2022) Immune Cell Metabolic Fitness for Life. Antibodies 11:2, pages 32.
Crossref
Shu Wu, Yuanlong Ge, Kaixuan Lin, Qianqian Liu, Haoxian Zhou, Qian Hu, Yong Zhao, Weifeng He & Zhenyu Ju. (2022) Telomerase RNA TERC and the PI3K-AKT pathway form a positive feedback loop to regulate cell proliferation independent of telomerase activity. Nucleic Acids Research 50:7, pages 3764-3776.
Crossref
Qian Zhu, Guoliang Qiao, Lefu Huang, Chang Xu, Deliang Guo, Shuo Wang, Jing Zhao, Yuguang Song, Bing Liu, Zheng Chen, Zhiyong Yang & Yufeng Yuan. (2022) Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology 12.
Crossref

Displaying 200 of 1324 citing articles. Use the download link below to view the full list of citing articles.

Download full citations list

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.